Circulating biomarkers of response to immunotherapy and immune-related adverse events

References

• Jiang Y, Zhao X, Fu J, et al. Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade. Front Immunol. 2020;11:1664–3224.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn. 2019;19(10):895–904.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary R. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224). DOI:10.1126/scitranslmed.3007094
   Web of Science ®Google Scholar
• Yeh CH, Spurgin J, Ford A, et al. Next-generation sequencing analysis of high-quality and high-quantity cell-free circulating DNA prepared from droplet volumes of patient plasma. J Clin Oncol. 2015;33(15_suppl):abstr e22008.
   Google Scholar
• Diaz JL, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J clin oncol. 2014;32(6):579–586.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842–1853.
   PubMed Web of Science ®Google Scholar
• Lee JH, Long GV, Boyd S, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130–1136.
   PubMed Web of Science ®Google Scholar
• Powles T, Carroll D, Chowdhury S, et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med. 2021;27(5):793–801.
   PubMed Web of Science ®Google Scholar
• Sobczuk P, Kozak K, Kopeć S, et al. The use of ctDNA for BRAF mutation testing in routine clinical practice in patients with advanced melanoma. Cancers (Basel). 2022;14(3):777.
   PubMed Web of Science ®Google Scholar
• Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76(3):441–451.
   PubMed Web of Science ®Google Scholar
• Gerin I, Bommer GT, McCoin CS, et al. Roles for mirna-378/378* in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab. 2010;299(2):E198–206.
   PubMed Web of Science ®Google Scholar
• Gurtan AM, Sharp PA. The role of mirnas in regulating gene expression networks. J Mol Biol. 2013;425(19):3582–3600.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–15529.
   PubMed Web of Science ®Google Scholar
• Kluiver S, Poppema D, de Jong T, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243–249.
   PubMed Web of Science ®Google Scholar
• Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64(9):3087–3095.
   PubMed Web of Science ®Google Scholar
• Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27(43):5651–5661.
   PubMed Web of Science ®Google Scholar
• Vahed S, Barzegari A, Saadat Y, et al. A microRNA isolation method from clinical samples. BioImpacts. 2016;6(1):25–31.
   PubMedGoogle Scholar
• Schneegans S, Lück L, Besler K, et al. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. Mol Oncol. 2020;14(5):1001–1015.
   PubMed Web of Science ®Google Scholar
• Halvorsen A, Sandhu V, Sprauten M, et al. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncologica. 2018;57(9):1225–1231.
   PubMed Web of Science ®Google Scholar
• Huber V, Vallacchi V, Fleming V, et al. Tumor-Derived MicroRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Investi. 2018;128(12):5505–5516.
   PubMed Web of Science ®Google Scholar
• Wang S, Song R, Wang Z, et al. S100A8/A9 in Inflammation. Front Immunol. 2018;9:1298.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Németh J, Angel P, et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72(11):1622–1631.
   PubMed Web of Science ®Google Scholar
• Wagner NB, Weide B, Gries M, et al. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer. 2019;7(1):343.
   PubMed Web of Science ®Google Scholar
• Wu Z, Jiang D, Huang X, et al. S100A8 as a promising biomarker and oncogenic immune protein in the tumor microenvironment: an integrative pancancer analysis. J Oncol. 2022;1-15:2022.
   Google Scholar
• Ş Ş, Ö M, Mersin S, et al. Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in hodgkin lymphoma. Int J Lab Hematol. 2021;43(4):638–644.
   PubMed Web of Science ®Google Scholar
• Simetić L, Blažičević K, Međugorac K, et al. Relative change in s100 as a biomarker of survival in patients with metastatic melanoma treated with pembrolizumab. Anticancer Res. 2020;40(4):2157–2163.
   PubMed Web of Science ®Google Scholar
• Wagner NB, Forschner A, Leiter U, et al. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer. 2018;119(3):339–346.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Versluis JM, Moritz R, et al. Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clin Chim Acta. 2022;533:71–78.
   PubMed Web of Science ®Google Scholar
• Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9(754). DOI:10.3389/fimmu.2018.00754
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Aref H, Refaat S. CRP evaluation in non-small cell lung cancer. Egyptian J Chest Dis Tuberculosis. 2014;63(3):717–722.
   Google Scholar
• Villaseñor A, Flatt SW, Marinac C, et al. Postdiagnosis C - reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomarkers Prev. 2013;23(1):189–199.
   PubMed Web of Science ®Google Scholar
• Nimptsch K, Aleksandrova K, Boeing H, et al. Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk. Int J Cancer. 2015;136(5):1181–1192.
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer. Hepatogastroenterology. 2014;61(136):2236–2240.
   PubMedGoogle Scholar
• Badakhshi H, Kaul D, Zhao KL. Association between the inflammatory biomarker, C-reactive protein, and the response to radiochemotherapy in patients with esophageal cancer. Mol Clin Oncol. 2016;4(4):643–647.
   PubMedGoogle Scholar
• Huang Y, Feng JF, Liu JS, et al. Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis. Ther Clin Risk Manag. 2015;11:89–94.
   PubMed Web of Science ®Google Scholar
• Baba H, Kuwabara K, Ishiguro T, et al. C-reactive protein as a significant prognostic factor for stage iv gastric cancer patients. Anticancer Res. 2013;33(12):5591–5596.
   PubMed Web of Science ®Google Scholar
• Oliveira KG, von Zeidler SV, Lamas AZ, et al. Relationship of inflammatory markers and pain in patients with head and neck cancer prior to anticancer therapy. Braz J Med Biol Res. 2014;47(7):600–604.
   PubMed Web of Science ®Google Scholar
• Klümper N, Saal J, Berner F, et al. Creactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer. 2022;10(3):e004024.
   PubMed Web of Science ®Google Scholar
• Chen J, Jing X, Deng X, et al. Prognostic value of serum C-reactive protein in pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2018;11(11):11789–11796.
   Web of Science ®Google Scholar
• Inoue D, Ozaka M, Matsuyama M, et al. Prognostic value of neutrophil–lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Japanese J Clin Oncol. 2015;45(1):61–66.
   PubMed Web of Science ®Google Scholar
• Riedl JM, Barth DA, Brueckl WM, et al. C-Reactive Protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a Bi-center study. Cancers (Basel). 2020;12(8):2319.
   PubMed Web of Science ®Google Scholar
• Simeone E, Gentilcore G, Giannarelli D, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63(7):675–683.
   PubMed Web of Science ®Google Scholar
• Carter J, Preall J, Grigaityte K, et al. Single T cell sequencing demonstrates the functional role of αβ TCR pairing in cell lineage and antigen specificity. Front Immunol. 2019;10:1664–3224.
   PubMed Web of Science ®Google Scholar
• Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842.
   PubMed Web of Science ®Google Scholar
• Park JE, Botting R, Conde CD, et al. A cell atlas of human thymic development defines T cell repertoire formation. Science. 2020;367(6480). DOI:10.1126/science.aay3224
   Web of Science ®Google Scholar
• Postow MA, Manuel M, Wong P, et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer. 2015;3(1):23.
   PubMedGoogle Scholar
• Arakawa A, Vollmer S, Tietze J, et al. Clonality of CD4(+) blood T cells predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma. Front Immunol. 2019;10:1336.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ji Z, Caushi JX, et al. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer. Clin Cancer Res. 2020;26(6):1327–1337.
   PubMed Web of Science ®Google Scholar
• Yao L, Jia G, Lu L, et al. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Int Immunopharmacol. 2020;85:106628.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III Melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–3814.
   PubMed Web of Science ®Google Scholar
• Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49–62.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13(1):211.
   PubMedGoogle Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730–741.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385.
   PubMed Web of Science ®Google Scholar
• Hu Y-B, Zhang Q, Li H-J, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6(S1):S8–S20.
   PubMedGoogle Scholar
• Nobashi T, Baratto L, Reddy SA, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med. 2019;44(4):e272–e279.
   PubMed Web of Science ®Google Scholar
• Albandar HJ, Fuqua J, Albandar JM, et al. Immune-related adverse events (irAE) in cancer Immune Checkpoint Inhibitors (ICI) and survival outcomes correlation: to rechallenge or not? Cancers (Basel). 2021;13(5):989.
   PubMed Web of Science ®Google Scholar
• Okada N, Kawazoe H, Takechi K, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther. 2019;41(1):59–67.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Grizzi G, Ghidini M, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2019;43(1):1–7.
   Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145(2):479–485.
   PubMed Web of Science ®Google Scholar
• Genova C, Rossi G, Rijavec E, et al. Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(5):573–585.
   PubMed Web of Science ®Google Scholar
• Uciechowski P, Dempke WCM. Interleukin-6: a Masterplayer in the cytokine network. Oncology. 2020;98(3):131–137.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Choi J, Kim I, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection. Transplantation. 2017;101(1):32–44.
   PubMed Web of Science ®Google Scholar
• Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. Cancer. 2007;110(9):1911–1928.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang L, Xu H, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022;20(187). DOI:10.1186/s12916-022-02356-7
   Google Scholar
• Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16(94). DOI:10.1186/s12967-018-1467-x
   PubMedGoogle Scholar
• Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–1379.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Okiyama N, Okune M, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab recativity. J Dermatol Sci. 2017;86(1):71–73.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The Il-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906.
   PubMed Web of Science ®Google Scholar
• Schindler K, Harmankaya K, Kuk D, et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. J clin oncol. 2014;32(15_suppl):9096.
   Web of Science ®Google Scholar
• Husain B, Kirchberger MC, Erdmann M, et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol. 2021;147(6):1623–1630.
   PubMed Web of Science ®Google Scholar
• Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors. Cancer Sci. 2020;111(5):1468–1477.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3(39). DOI:10.1186/s40425-015-0081-1
   PubMedGoogle Scholar
• Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(7):1090–1100.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010;106:91–111.
   PubMed Web of Science ®Google Scholar
• Rumble JM, Huber AK, Krishnamoorthy G, et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med. 2015;212(1):23–35.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kakizaki A, Furudate S, et al. A possible interaction between periostin and CD163 + skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid. Exp Dermatol. 2017;26(12):1193–1198.
   PubMed Web of Science ®Google Scholar
• Buckland J. Rheumatoid arthritis: citrullination alters the inflammatory properties of chemokines in inflammatory arthritis. Nat Rev Rheumatol. 2014;10(8):446.
   PubMedGoogle Scholar
• Fujimura T, Sato Y, Tanita K, et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget. 2018;9(21):15542–15551.
   PubMedGoogle Scholar
• Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010;47(7–8):1650–1660.
   PubMed Web of Science ®Google Scholar
• Greisen SR, Møller HJ, Stengaard-Pedersen K, et al. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. Clin Exp Rheumatol. 2015;33(4):498–502.
   PubMed Web of Science ®Google Scholar
• Fujimura T. Stromal factors as a target for immunotherapy in melanoma and non-melanoma skin cancers. Int J Mol Sci. 2022;23(7):4044.
   PubMed Web of Science ®Google Scholar
• Furudate S, Fujimura T, Kakizaki A, et al. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides. Exp Dermatol. 2016;25(2):107–112.
   PubMed Web of Science ®Google Scholar
• Gudd CLC, Au L, Triantafyllou E, et al. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. J Hepatol. 2021;75(1):177–189.
   PubMed Web of Science ®Google Scholar
• Diehl A, Yarchoan M, Hopkins A, et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 2017;8(69):114268–114280.
   PubMedGoogle Scholar
• Nakamura Y, Tanaka R, Maruyama H, et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 2019;49(5):431–437.
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Yoshino K, Otsuka A, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci. 2017;88(2):225–231.
   PubMed Web of Science ®Google Scholar
• Da Gama Duarte J, Parakh S, Andrews M, et al. Autoantibodies may predict immune-related toxicity: results from a Phase I study of intralesional Bacillus Calmette-Guérin followed by ipilimumab in patients with advanced metastatic melanoma. Front Immunol. 2018;9:411.
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.
   PubMed Web of Science ®Google Scholar
• Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–1480.
   PubMed Web of Science ®Google Scholar
• Umeguchi H, Takenoshita H, Inoue H, et al. Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report. J Oncol Pract. 2018;14(7):449–451.
   PubMed Web of Science ®Google Scholar
• Lupi I, Brancatella A, Cetani F, et al. Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism. J Clin Endocrinol Metab. 2020;105(5):dgaa092.
   PubMed Web of Science ®Google Scholar
• Piranavan P, Li Y, Brown E, et al. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab. 2019;104(2):550–556.
   PubMed Web of Science ®Google Scholar
• Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109(11):3583–3590.
   PubMed Web of Science ®Google Scholar
• Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77(6):1322–1330.
   PubMed Web of Science ®Google Scholar
• Subudhi SK, Aparicio A, Gao J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Nat Acad Sci. 2016;113(42):11919–11924.
   PubMed Web of Science ®Google Scholar
• Lozano AX, Chaudhuri AA, Nene A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28(2):353–362.
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):10391.
   PubMed Web of Science ®Google Scholar
• Botticelli A, Vernocchi P, Marini F, et al. Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. J Transl Med. 2020;18(1):49.
   PubMed Web of Science ®Google Scholar
• Schett A, Rothschild SI, Curioni-Fontecedro A, et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol. 2020;85(1):121–131.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97.
   PubMed Web of Science ®Google Scholar